Chemocentryx, Inc.

Jeffrey P McMahon

Penglie Zhang

Junfa Fan

Jay Patrick Powers

Venkat Reddy Mali

Ju Yang

Antoni Krasinski

Yibin Zeng

Xi Chen

Manmohan Reddy Leleti

Christopher W Lange

Rajinder Paul Singh

Rebecca M Lui

Sreenivas Punna

Hiroko Tanaka

Jaroslaw Kalisiak

Viengkham Malathong

Dean R Dragoli

Chao Yu

Pingchen Fan

Darren J McMurtrie

Lianfa Li

Howard S Roth

Yandong Li

Trevor T Charvat

Yu Wang

Juan Carlos Jaen

Mark M Gleason

James J Campbell

Karen Ebsworth

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

CXCR7 antagonists

Compounds are provided as chemokine inhibitors having the structure:

Modulators of chemokine receptors

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R, R, R, R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Immunomodulator compounds

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II):

Macrocyclic immunomodulators

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C&#x2014;X&#x2014;C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C&#x2014;X&#x2014;C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula: 

Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Substituted anilines as CCR(4) antagonists

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): 

Compounds are provided as inhibitors of CXCR2, having the structure: 

Inhibitors of CXCR2

Compounds are provided as chemokine inhibitors having the structure: 

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

Growing community of inventors

Mountain View, CA, United States of America

Jeffrey P McMahon